帕金森病和肠道微生物群的联系:揭示生态失调和探索治疗视野

IF 2.8 3区 医学 Q2 NEUROSCIENCES
Satyam Yadav, Rojin G. Raj
{"title":"帕金森病和肠道微生物群的联系:揭示生态失调和探索治疗视野","authors":"Satyam Yadav,&nbsp;Rojin G. Raj","doi":"10.1016/j.neuroscience.2025.07.003","DOIUrl":null,"url":null,"abstract":"<div><div>Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by dopaminergic neuronal loss, α-synuclein aggregation, and sustained neuroinflammation. Emerging evidence supports the gut-brain-microbiota axis as a pivotal player in the disease’s pathogenesis. Dysbiosis, disruptions in the gut microbial composition, has been consistently observed in individuals with PD, with notable reductions in beneficial, short-chain fatty acid-producing bacteria and elevations in pro-inflammatory microbial species. These alterations contribute to increased intestinal permeability, systemic inflammation, and heightened neuroinflammatory responses that may drive α-synuclein misfolding and dopaminergic degeneration. In addition, microbial metabolites, including lipopolysaccharides and amyloid proteins such as curli, may promote neurodegeneration via immune and molecular mimicry pathways. Recent advances highlight the bidirectional influence of the microbiota-gut-brain axis on PD symptoms, ranging from motor deficits to non-motor features like constipation, depression, and cognitive decline. Several microbiota-modulating interventions, including probiotics, prebiotics, dietary strategies, antibiotics, and fecal microbiota transplantation, have demonstrated neuroprotective potential in both preclinical and clinical contexts. However, inter-individual variability, methodological heterogeneity, and the absence of longitudinal, multi-omics-integrated studies limit current understanding. The gut microbiome also holds promise as a non-invasive biomarker for early PD detection and prognosis, though standardization remains a challenge. Future research must clarify causal mechanisms, optimize therapeutic delivery, and integrate genetic, metabolic, and environmental data to advance precision medicine approaches. This review consolidates current knowledge on gut microbiota’s role in PD pathophysiology and therapeutic innovation, providing a roadmap for future research directions.</div></div>","PeriodicalId":19142,"journal":{"name":"Neuroscience","volume":"581 ","pages":"Pages 1-15"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Parkinson’s disease and the gut microbiota connection: unveiling dysbiosis and exploring therapeutic horizons\",\"authors\":\"Satyam Yadav,&nbsp;Rojin G. Raj\",\"doi\":\"10.1016/j.neuroscience.2025.07.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by dopaminergic neuronal loss, α-synuclein aggregation, and sustained neuroinflammation. Emerging evidence supports the gut-brain-microbiota axis as a pivotal player in the disease’s pathogenesis. Dysbiosis, disruptions in the gut microbial composition, has been consistently observed in individuals with PD, with notable reductions in beneficial, short-chain fatty acid-producing bacteria and elevations in pro-inflammatory microbial species. These alterations contribute to increased intestinal permeability, systemic inflammation, and heightened neuroinflammatory responses that may drive α-synuclein misfolding and dopaminergic degeneration. In addition, microbial metabolites, including lipopolysaccharides and amyloid proteins such as curli, may promote neurodegeneration via immune and molecular mimicry pathways. Recent advances highlight the bidirectional influence of the microbiota-gut-brain axis on PD symptoms, ranging from motor deficits to non-motor features like constipation, depression, and cognitive decline. Several microbiota-modulating interventions, including probiotics, prebiotics, dietary strategies, antibiotics, and fecal microbiota transplantation, have demonstrated neuroprotective potential in both preclinical and clinical contexts. However, inter-individual variability, methodological heterogeneity, and the absence of longitudinal, multi-omics-integrated studies limit current understanding. The gut microbiome also holds promise as a non-invasive biomarker for early PD detection and prognosis, though standardization remains a challenge. Future research must clarify causal mechanisms, optimize therapeutic delivery, and integrate genetic, metabolic, and environmental data to advance precision medicine approaches. This review consolidates current knowledge on gut microbiota’s role in PD pathophysiology and therapeutic innovation, providing a roadmap for future research directions.</div></div>\",\"PeriodicalId\":19142,\"journal\":{\"name\":\"Neuroscience\",\"volume\":\"581 \",\"pages\":\"Pages 1-15\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0306452225007651\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0306452225007651","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

帕金森病(PD)是一种进行性神经退行性疾病,其特征是多巴胺能神经元丧失、α-突触核蛋白聚集和持续的神经炎症。新出现的证据支持肠-脑微生物群轴在该疾病的发病机制中起关键作用。生态失调,肠道微生物组成的破坏,在PD患者中一直被观察到,有益的短链脂肪酸产生细菌显著减少,促炎微生物物种增加。这些改变导致肠通透性增加,全身性炎症,神经炎症反应增强,可能导致α-突触核蛋白错误折叠和多巴胺能变性。此外,微生物代谢物,包括脂多糖和淀粉样蛋白如curli,可能通过免疫和分子模拟途径促进神经变性。最近的进展强调了微生物-肠-脑轴对PD症状的双向影响,从运动缺陷到非运动特征,如便秘、抑郁和认知能力下降。几种微生物群调节干预措施,包括益生菌、益生元、饮食策略、抗生素和粪便微生物群移植,在临床前和临床背景下都显示出神经保护潜力。然而,个体间差异、方法异质性以及缺乏纵向、多组学整合研究限制了目前的理解。肠道微生物组也有望作为PD早期检测和预后的非侵入性生物标志物,尽管标准化仍然是一个挑战。未来的研究必须阐明因果机制,优化治疗方法,并整合遗传、代谢和环境数据,以推进精准医学方法。本文综述了肠道微生物群在PD病理生理和治疗创新中的作用,为未来的研究方向提供了路线图。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Parkinson’s disease and the gut microbiota connection: unveiling dysbiosis and exploring therapeutic horizons

Parkinson’s disease and the gut microbiota connection: unveiling dysbiosis and exploring therapeutic horizons
Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by dopaminergic neuronal loss, α-synuclein aggregation, and sustained neuroinflammation. Emerging evidence supports the gut-brain-microbiota axis as a pivotal player in the disease’s pathogenesis. Dysbiosis, disruptions in the gut microbial composition, has been consistently observed in individuals with PD, with notable reductions in beneficial, short-chain fatty acid-producing bacteria and elevations in pro-inflammatory microbial species. These alterations contribute to increased intestinal permeability, systemic inflammation, and heightened neuroinflammatory responses that may drive α-synuclein misfolding and dopaminergic degeneration. In addition, microbial metabolites, including lipopolysaccharides and amyloid proteins such as curli, may promote neurodegeneration via immune and molecular mimicry pathways. Recent advances highlight the bidirectional influence of the microbiota-gut-brain axis on PD symptoms, ranging from motor deficits to non-motor features like constipation, depression, and cognitive decline. Several microbiota-modulating interventions, including probiotics, prebiotics, dietary strategies, antibiotics, and fecal microbiota transplantation, have demonstrated neuroprotective potential in both preclinical and clinical contexts. However, inter-individual variability, methodological heterogeneity, and the absence of longitudinal, multi-omics-integrated studies limit current understanding. The gut microbiome also holds promise as a non-invasive biomarker for early PD detection and prognosis, though standardization remains a challenge. Future research must clarify causal mechanisms, optimize therapeutic delivery, and integrate genetic, metabolic, and environmental data to advance precision medicine approaches. This review consolidates current knowledge on gut microbiota’s role in PD pathophysiology and therapeutic innovation, providing a roadmap for future research directions.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neuroscience
Neuroscience 医学-神经科学
CiteScore
6.20
自引率
0.00%
发文量
394
审稿时长
52 days
期刊介绍: Neuroscience publishes papers describing the results of original research on any aspect of the scientific study of the nervous system. Any paper, however short, will be considered for publication provided that it reports significant, new and carefully confirmed findings with full experimental details.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信